成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>251303-04-5

251303-04-5

中文名稱 ERTIPROTAFIB
英文名稱 Ertiprotafib
CAS 251303-04-5
分子式 C31H27BrO3S
分子量 559.51
MOL 文件 251303-04-5.mol
更新日期 2024/07/24 18:26:22
251303-04-5 結(jié)構(gòu)式 251303-04-5 結(jié)構(gòu)式

基本信息

中文別名
化合物 T15243
英文別名
PTP 112
Ertiprotafib
Benzenepropanoic acid, a-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thien-4-yl)-2,6-dimethylphenoxy]-,(aR)-
Benzenepropanoic acid, α-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thien-4-yl)-2,6-dimethylphenoxy]-, (αR)-
所屬類別
生物化工:抑制劑

物理化學(xué)性質(zhì)

沸點(diǎn)690.7±55.0 °C(Predicted)
密度1.376±0.06 g/cm3(Predicted)
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度溶于二甲基亞砜
酸度系數(shù)(pKa)3.21±0.10(Predicted)
形態(tài)Solid
顏色Light yellow to yellow
化合物 T15243價(jià)格(試劑級(jí))
報(bào)價(jià)日期產(chǎn)品編號(hào)產(chǎn)品名稱CAS號(hào)包裝價(jià)格
2025/02/08HY-19383化合物 T15243
Ertiprotafib
251303-04-51 mg1590元
2025/02/08HY-19383化合物 T15243
Ertiprotafib
251303-04-55 mg3500元
2025/02/08HY-19383化合物 T15243
Ertiprotafib
251303-04-510 mM * 1 mLin DMSO4308元

常見問題列表

生物活性
Ertiprotafib 是 PTP1B, IKK-β 的抑制劑,其 IC50 值分別是 1.6 μM,400 nM,同時(shí)也是PPARα/PPARβ 的激動(dòng)劑,其 EC50 值為 ~1 μM。
靶點(diǎn)

PTP1B

1.6 μM (IC 50 )

IKK-β

400 nM (IC 50 )

PPARα

~1 μM (EC 50 )

PPARβ

~1 μM (EC 50 )

體外研究

Ertiprotafib is a potent inhibitor of IKK-β, with an IC 50 value of 400±40 nM, which is much lower than that required for the half-maximal inhibition of the p-nitrophenyl phosphatase activity of PTP1B. The reported IC 50 value of Ertiprotafib against PTP1B ranges from 1.6 to 29 μM depending on the assay conditions. Ertiprotafib is at least a dual PPARα and PPARβ agonist with EC 50 values for transactivation of 1 μM. Such activities readily explain the observations with suprapharmacologic doses of these.

體內(nèi)研究

As seen with treatment of ob/ob mice, both Ertiprotafib and compound 3 seem to significantly improve glucose metabolism in rats. At 25 mg/kg/day, these compounds decrease both fasting blood glucose and insulin levels compared with vehicle treated rats. Furthermore, both Ertiprotafib and compound 3 increase glucose disposal after an oral challenge. It is noteworthy that lipid levels are also reduced in treated animals. Both triglyceride and free fatty acid levels are substantially reduced in rats treated with 25 mg/kg/day of either compound. To summarize, both Ertiprotafib and compound 3 seem to be robust agents in improving glucose utilization in fa/fa rats while also decreasing lipid levels in these animals. Decreased lipid levels may be unexpected for a pure PTP1b inhibitor. It is more telling, as mentioned above, that rats treated with suprapharmacologic doses of Ertiprotafib show signs of PPAR family activation.

"251303-04-5" 相關(guān)產(chǎn)品信息